46 research outputs found
Myocardial disease caused by adriamycin. Experimental animal models and possible pharmacologic prevention.
No full textAdriamycin experimental cardiomyopathy in Swiss mice. Different effects of two calcium antagonistic drugs on ADM - induced cardiomyopathy.
No full textThe fluorescent probe Bodypy-FL-Verapamil is a substrate for both P-glycoprotein and Multidrug resistance-related protein (MRP)-1.
No full textEffects of ICRF 159 on adriamycin-induced cardiomyopathy in rats.
No full textThe effect of ICRF 159 on adriamycin (ADR) cardiotoxicity and on total myocardial calcium content was examined in rats. ICRF 159 did not increase the survival time of ADR-treated animals; however the histological findings showed a significant prevention of ADR-induced cardiomyopathy (CMP) by ICRF. The total myocardial calcium content of animals treated with ADR was significantly higher, while no significant difference was seen in animals pretreated with ICRF 159 as compared with controls. As these findings suggested a role of calcium in ADR CMP and in the pharmacological action of ICRF in this disease, we also tested a closely related chelating agent, EDTA. This molecule decreased myocardial calcium levels in ADR-treated animals almost to normal values; however the histological cardiac alterations were not prevented
Degranulation and adriamycin uptake in beige mice mast cells with giant secretory granules
No full textUltrastructural and biochemical studies on mast cell exocytosis induced by adriamycin at different temperatures
No full text
Evidence for the lack of involvement of free radicals in adriamycin-induced histamine release from rat peritoneal cells.
No full text
Characterization of histamine secretion induced by anthracyclines in rat peritoneal mast cells.
No full text
